## OFFICE OF THE SECRETARY OF STATE

LAVONNE GRIFFIN-VALADE SECRETARY OF STATE

CHERYL MYERS
DEPUTY SECRETARY OF STATE
AND TRIBAL LIAISON



## ARCHIVES DIVISION

STEPHANIE CLARK DIRECTOR

800 SUMMER STREET NE SALEM, OR 97310 503-373-0701

## PERMANENT ADMINISTRATIVE ORDER

BP 3-2024

**CHAPTER 855** 

**BOARD OF PHARMACY** 

**FILED** 

02/15/2024 2:40 PM ARCHIVES DIVISION SECRETARY OF STATE & LEGISLATIVE COUNSEL

FILING CAPTION: Pharmacists; Collaborative Drug Therapy Management (CDTM)

EFFECTIVE DATE: 03/01/2024

AGENCY APPROVED DATE: 02/09/2024

CONTACT: Rachel Melvin 800 NE Oregon St., Suite 150 Filed By:

971-673-0001 Portland, OR 97232 Rachel Melvin

pharmacy.rulemaking@bop.oregon.gov Rules Coordinator

ADOPT: 855-115-0315

NOTICE FILED DATE: 12/22/2023

RULE SUMMARY: Relocates existing CDTM rules from OAR 855-019-0260 to OAR 855-115-0315. The board adopted Division 115 Pharmacists rules in August, October, December 2023 and February 2024, effective 3/1/2024 which

replaces Division 019.

**CHANGES TO RULE:** 

## 855-115-0315

Collaborative Drug Therapy Management

(1) As used in this rule "Collaborative Drug Therapy Management" (CDTM) means the participation by a practitioner and a pharmacist in the management of drug therapy pursuant to a written agreement that includes information on the dosage, frequency, duration and route of administration of the drug, authorized by a practitioner and initiated upon a prescription order for an individual patient and:¶

(a) Is agreed to by one practitioner and one pharmacist; or ¶

(b) Is agreed to by one or more practitioners in a single organized medical group, such as a hospital medical staff, clinic or group practice, including but not limited to organized medical groups using a pharmacy and therapeutics committee, and one or more pharmacists.¶

(2) A pharmacist shall engage in collaborative drug therapy management with a practitioner only under a written arrangement that includes:¶

(a) The identification, either by name or by description, of each of the participating pharmacists;¶

(b) The identification, by name or description, of each of the participating practitioners or group of practitioners;¶

(c) The name of the principal pharmacist and practitioner who are responsible for development, training, administration, and quality assurance of the arrangement;¶

(d) The types of decisions that the pharmacist is allowed to make, which may include: ¶

(A) A detailed description of the types of diseases, drugs, or drug categories involved, and the activities allowed in each case;¶

(B) A detailed description of the methods, procedures, decision criteria, and plan the pharmacist is to follow when conducting allowed activities;¶

(C) A detailed description of the activities the pharmacist is to follow including documentation of decisions made and a plan or appropriate mechanism for communication, feedback, and reporting to the practitioner concerning specific decisions made. In addition to the agreement, documentation shall occur on the prescription record, patient profile, a separate log book, or in some other appropriate system;¶

- (D) Circumstances which will cause the pharmacist to initiate communication with the practitioner, including but not limited to the need for a new prescription order and a report of a patient's therapeutic response or any adverse effect.¶
- (e) Training requirement for pharmacist participation and ongoing assessment of competency, if necessary;¶ (f) Quality assurance and periodic review by a panel of the participating pharmacists and practitioners;¶ (g) Authorization by the practitioner for the pharmacist to participate in collaborative drug therapy; and¶ (h) A requirement for the collaborative drug therapy arrangement to be reviewed and updated, or discontinued at least every two years.¶
- (3) The collaborative drug therapy arrangement and associated records must be kept on file in the pharmacy and made available to any appropriate health licensing board upon request.¶
- (4) Nothing in this rule shall be construed to allow the rapeutic substitution outside of the CDTM agreement. Statutory/Other Authority: ORS 689.205
- Statutes/Other Implemented: ORS 689.151, ORS 689.155